NYB.AI and Pnaseer Inc. have announced a strategic partnership focused on accelerating innovation in hair follicle regeneration through the integration of artificial intelligence and targeted drug delivery technologies. The collaboration, formalized in July 2025, combines NYB.AI's proprietary AI platform for compound-target interaction prediction with Pnaseer's advanced bio-nanoparticle delivery system to enable efficient development of therapeutic compounds for regenerative medicine.
Project Follica Initiative
At the core of this collaboration is Project Follica, a joint initiative that aims to discover and develop a new generation of compounds that can stimulate hair follicle regeneration with higher efficacy and safety. The project focuses on both natural and synthetic molecules, selected through advanced in silico screening and validated through in vitro assays.
NYB.AI's proprietary AI technology enables rapid prediction of compound-target interactions in hair biology, significantly accelerating early-stage discovery. The platform will prioritize candidates with strong biological relevance by analyzing extensive compound libraries. Pnaseer's delivery platform ensures optimal formulation and distribution of actives to target tissues, designed to improve therapeutic precision, increase bioavailability, and target specific tissues more effectively.
Strategic Objectives and Outcomes
Project Follica aims to deliver transformative impact through three key outcomes. First, it will build an AI-informed database of natural and synthetic compounds, mapped to critical biological pathways involved in hair follicle regeneration. Second, the collaboration will develop a scientifically validated, formulation-ready prototype for preclinical evaluation and future product development. Third, the project will create a scalable AI discovery framework tailored for dermatological and regenerative medicine applications.
"With Project Follica, we are not only accelerating compound discovery but also redefining how the industry approaches hair regeneration. The combination of AI and deep biological insights allows us to uncover promising bioactives that were previously overlooked," said Giang Nguyen, CEO of NYB.AI.
Technology Integration and Validation
The partnership brings together complementary strengths from both organizations. NYB.AI contributes a robust computational platform capable of modeling and predicting molecular interactions across complex biological networks. Pnaseer enhances this capability with its proprietary delivery technology, designed to improve therapeutic precision and targeting effectiveness.
"Hair regeneration requires a highly targeted, multidisciplinary approach. By combining NYB's AI insights with our advanced delivery technology, we aim to unlock novel solutions that can overcome current limitations in efficacy and safety," said Dr. Shin Sung Min, Co-Founder & Global Business Development Director at Pnaseer Inc.
The collaboration includes comprehensive validation through in silico simulations, in vitro assays, formulation optimization, and preclinical readiness. Both parties will share critical research resources, including compound databases, biological data, and AI tools, to ensure scientific rigor and project efficiency.
Company Backgrounds
NYB.AI is a biotech company using AI and biological data to understand drug-target interactions in disease pathways. Through its AI platform and compound libraries, NYB.AI identifies promising therapeutic molecules and optimizes them for effectiveness using advanced machine learning techniques to accelerate the discovery of next-generation treatments for cancer and chronic diseases.
Pnaseer Inc. is a biotechnology company specializing in the development of advanced drug delivery technologies. The company is dedicated to enhancing the therapeutic performance of approved drugs through the application of its proprietary bio-nanoparticle platform, supporting a broad range of applications from pharmaceutical formulation and manufacturing to wellness-focused treatments.
